Nano-X Imaging Ltd. Holds Analyst Day, Discusses Future Products

Ticker: NNOX · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1795251

Sentiment: neutral

Topics: analyst-day, product-development, regulatory-update

TL;DR

Nanox held an Analyst Day on 9/20, showing off commercial progress and future products still in development.

AI Summary

On September 20, 2024, Nano-X Imaging Ltd. held an Analyst Day to discuss its commercial, clinical, and regulatory progress. The company also provided an outlook on future products currently in development and awaiting regulatory clearance.

Why It Matters

This event provides investors and analysts with an update on the company's strategic direction, product pipeline, and regulatory milestones, which are crucial for future revenue generation.

Risk Assessment

Risk Level: medium — The filing discusses future products in development that are not yet regulatory cleared, indicating inherent risks in their commercialization and market acceptance.

Key Players & Entities

FAQ

What was the primary purpose of Nano-X Imaging Ltd.'s Analyst Day on September 20, 2024?

The Analyst Day was held to present recent commercial, clinical, and regulatory pathways, and to provide a glimpse into future products in development.

What specific information was shared regarding future products?

The company provided a glance to its future products which are in development stages and are not yet regulatory cleared.

Is the entire presentation from the Analyst Day included with this filing?

No, a copy of the presentation is attached as Exhibit 99.1, excluding a VR demo.

What is Nano-X Imaging Ltd.'s principal executive office address?

The principal executive office is located at Ofer Tech Park, 94 Shlomo Shmeltzer Road, Petach Tikva, Israel, 4970602.

Under which form does Nano-X Imaging Ltd. typically file its annual reports?

Nano-X Imaging Ltd. files its annual reports under cover of Form 20-F.

Filing Stats: 203 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2024-09-23 09:16:00

Filing Documents

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F CONTENTS On Friday 20, 2024, Nano-X Imaging Ltd. (the “ Company ”) held an Analyst Day, during which the Company presented recent commercial, clinical and regulatory pathways, and provided a glance to its future products which are in development stages and are not yet regulatory cleared. A copy of the presentation, excluding a VR demo, is attached hereto as Exhibit 99.1 and incorporated herein by reference. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NANO-X IMAGING LTD (Registrant) Date: September 23, 2024 By: /s/ Ran Daniel Ran Daniel Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing